<DOC>
	<DOCNO>NCT01836861</DOCNO>
	<brief_summary>This open-label , 2-period , absorption , distribution , metabolism excretion ( ADME ) absolute bioavailability study 6 healthy adult male subject .</brief_summary>
	<brief_title>IPI-145 ADME Absolute Bioavailability Study</brief_title>
	<detailed_description>In Period 1 , subject receive single oral dose 25 mg IPI-145 , follow 15-minute IV infusion approximately 2.8 Î¼g 14C-IPI-145 contain 14.8 kBq radioactivity . In Period 2 , subject receive single dose 25 mg 14C-IPI-145 oral suspension , contain approximately 3.15 MBq radioactivity . There washout period least 14 day Period 1 Period 2 .</detailed_description>
	<criteria>Males , 18 45 year age , inclusive Body Mass Index ( BMI ) : 18.030.0 kg/m2 In good health , determine clinically significant finding medical history , physical examination ( Checkin ) , 12lead ECG , vital sign Provision sign date , write informed consent prior study specific procedure Evidence clinically significant medical condition History gastrointestinal surgery may affect drug absorption Positive indeterminate QuantiFERONTB Gold test screen Any active infection time screen admission Participation another ADME study radiation burden &gt; 0.1 mSv period 1 year screen Irregular defecation pattern ( less per 2 day )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Phase I</keyword>
	<keyword>healthy male volunteer</keyword>
	<keyword>ADME</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>PI3K inhibitor</keyword>
	<keyword>Absorption</keyword>
	<keyword>Distribution</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
	<keyword>safety</keyword>
</DOC>